164 related articles for article (PubMed ID: 26867030)
1. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
Giantzi V; Karapanayiotides T; Lagoudaki R; Poulatsidou KN; Lourbopoulos A; Daniilidis M; Taskos N; Milonas I; Grigoriadis N
Eur Neurol; 2016; 75(1-2):82-8. PubMed ID: 26867030
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
3. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
5. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM
Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
[TBL] [Abstract][Full Text] [Related]
6. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
[TBL] [Abstract][Full Text] [Related]
7. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
[TBL] [Abstract][Full Text] [Related]
8. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
[TBL] [Abstract][Full Text] [Related]
11. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
12. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera.
Prince HE; Lapé-Nixon M; Audette C; Van Horn K
J Neuroimmunol; 2007 Oct; 190(1-2):165-9. PubMed ID: 17889376
[TBL] [Abstract][Full Text] [Related]
13. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
15. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
16. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
17. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
18. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
[TBL] [Abstract][Full Text] [Related]
19. Can we get rid of neutralizing antibodies against interferon-β?
Buttmann M; Toyka KV
Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143
[No Abstract] [Full Text] [Related]
20. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
